

Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday, 21 March 2018, 10:00 – 17:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Chair Professor Stephen O'Brien	Present for all notes
	2. Mr Kamal Balakrishnan	Present for all notes
	3. Dr Alex Cale	Present for all notes
	4. Mr Michael Chambers	Present for notes 1-16 & 29-39
	5. Mr David Chandler	Present for notes 16-39
	6. Ms Gail Coster	Present for all notes
	7. Dr Prithwiraj Das	Present for all notes
	8. Dr Natalie Hallas	Present for all notes
	9. Mr John Hampson	Present for all notes
	10. Dr Nigel Langford	Present for all notes
	11. Dr Rubin Minhas	Present for all notes
	12. Dr Richard Nicholas	Present for all notes
	13. Prof Andrew Renehan	Present for all notes
	14. Dr Peter Selby	Present for all notes
	15. Dr Paul Tappenden	Present for all notes
	16. Dr Judith Wardle	Present for all notes

In attendance:

Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Linda Landells	Associate Director, National Institute for Health and Care Excellence	Present for notes 17-25
Stephanie Callaghan	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Tanith Musson	Administrator, National Institute for Health and Care Excellence	Present for all notes

Kirsty Pitt	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1-16 & 29-39
Alex Filby	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1-16
Victoria Kelly	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17-28
Nicola Hay	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 17-28

Non-public attendees:

Bram Ramaekers	ERG representative	Present for notes 5-13
Rob Riemsma	ERG representative	Present for notes 5-13
Steve Edwards	ERG representative	Present for notes 17-25
Mariana Bacelar	ERG representative	Present for notes 17-25
Charlotta Karner	ERG representative	Present for notes 17-25
Nigel Russell	Clinical Expert	Present for notes 5-13
Graham Collins	Clinical Expert	Present for notes 17-25
Kirsty Thomson	Clinical Expert	Present for notes 17-25
David Thomson	NHS Commissioning Expert	Present for all notes
Clement Francois	Company representative	Present for notes 5-13
Weiwei Xu	Company representative	Present for notes 5-13
Eugene Benson	Company representative	Present for notes 17-25
Anthony Hatswell	Company representative	Present for notes 17-25
Sachin Patel	Company representative	Present for notes 29-36
Greg Medalla	Company representative	Present for notes 29-36
Leslie Hayes	NICE observer	Present for all notes
Henry Edwards	NICE observer	Present for notes 17-25
Tosin Oladapo	NICE observer	Present for all notes
Adeolu Grillo	NICE observer	Present for all notes
Emma Kent	NICE observer	Present for notes 17-25
Laura Worthington	NICE observer	Present for notes 17-25
Nicola Ace	PHE observer	Present for notes 17-25
Stephen Benson	PHE observer	Present for notes 17-25
Sarah Lawton	PHE observer	Present for notes 17-25
Louise Miller	PHE observer	Present for notes 17-25

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of arsenic trioxide for treating acute promyelocytic leukaemia [ID446], brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma (CDF Review of TA446) [ID1366] and midostaurin for untreated acute myeloid leukaemia [ID894]

2. The Chair welcomed Dr Alex Cale and Dr Rubin Minhas to their first meeting as a member of the Appraisal Committee
3. The Chair informed the Committee of the non-public observers at this meeting: Nicola Ace, Stephen Benson, Henry Edwards, Adeolu Grillo, Leslie Hayes, Emma Kent, Sarah Lawton, Louise Miller, Tosin Oladapo, Laura Worthington
4. Apologies were received from Professor Andrea Manca, Professor Matt Stevenson, Dr Derek Ward and Professor Robert Walton

Appraisal of arsenic trioxide for treating acute promyelocytic leukaemia [ID446]

Part 1 – Open session

5. The Chair welcomed the invited experts: Bram Ramaekers, Rob Riemsma, Nigel Russell to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Teva to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Mr Kamal Balakrishnan, Dr Alex Cale, Mr Michael Chambers, Ms Gail Coster, Dr Prithwiraj Das, Dr Natalie Hallas, Mr John Hampson, Dr Nigel Langford, Dr Rubin Minhas, Dr Richard Nicholas, Prof Andrew Renehan, Professor Peter Selby, Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of arsenic trioxide for treating acute promyelocytic leukaemia [ID446]
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of arsenic trioxide for treating acute promyelocytic leukaemia [ID446]
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of arsenic trioxide for treating acute promyelocytic leukaemia [ID446]
 - 9.2. Nigel Russell declared a personal non-specific financial interest as he has participated in advisory boards for Teva
 - 9.2.1. It was agreed that this declaration would not prevent Nigel Russell from participating in this section of the meeting

10. The Chair introduced the lead team, Andrew Renehan, Michael Chambers and Judith Ward, who gave presentations on the clinical effectiveness and cost effectiveness of arsenic trioxide for treating acute promyelocytic leukaemia [ID446]
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of arsenic trioxide for treating acute promyelocytic leukaemia [ID446]
 - 15.1. The committee decision was based on consensus
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma (CDF Review of TA446) [ID1366]

Part 1 – Open session

17. The Chair welcomed the invited experts: Mariana Bacelar, Steve Edwards, Charlotta Karner, Graham Collins and Kirsty Thomson to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from Takeda to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
 - 19.1. Mr Kamal Balakrishnan, Dr Alex Cale, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Dr Prithwiraj Das, Dr Natalie Hallas, Mr John Hampson, Dr Nigel Langford, Dr Rubin Minhas, Dr Richard Nicholas, Prof Stephen O’Brien, Prof Andrew Renehan, Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma (CDF Review of TA446) [ID1366]

- 19.2. Dr Michael Chambers is noted to be absent for this appraisal due to conflicts as he declared a personal, non-specific, financial interest in working part-time on contract for Takeda
20. The Chair asked all NICE Staff to declare any relevant interests.
- 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma (CDF Review of TA446) [ID1366]
21. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
- 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma (CDF Review of TA446) [ID1366]
- 21.2. Graham Collins declared a personal non-specific financial interest as he has previously received honoraria for advisory work for Takeda
21.2.1. It was agreed that this declaration would not prevent Graham Collins from participating in this section of the meeting
22. The Chair introduced the lead team, David Chandler and Paul Tappenden, who gave presentations on the clinical effectiveness and cost effectiveness of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma (CDF Review of TA446) [ID1366]
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.
27. The Committee continued to discuss the clinical and cost effectiveness of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma (CDF Review of TA446) [ID1366]

- 27.1. The committee decision was based on consensus
28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of midostaurin for untreated acute myeloid leukaemia [ID894]

Part 1 – Open session

29. The Chair welcomed company representatives from Novartis to the meeting.
30. The Chair asked all Committee members to declare any relevant interests
- 30.1. Chair Professor Stephen O'Brien, Mr Kamal Balakrishnan, Dr Alex Cale, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Dr Prithwiraj Das, Dr Natalie Hallas, Mr John Hampson, Dr Nigel Langford, Dr Rubin Minhas, Dr Richard Nicholas, Prof Andrew Renehan, Professor Peter Selby, Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of midostaurin for untreated acute myeloid leukaemia [ID894]
31. The Chair asked all NICE Staff to declare any relevant interests.
- 31.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of midostaurin for untreated acute myeloid leukaemia [ID894]
32. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests
33. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
34. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
35. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
36. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

37. Discussion on confidential information continued. This information was supplied by the company.
38. The Committee continued to discuss the clinical and cost effectiveness of midostaurin for untreated acute myeloid leukaemia [ID894]
 - 38.1. The committee decision was based on consensus.
39. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

Thursday 26 April 2018 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT